Skip to main content
. 2021 May 13;12:681424. doi: 10.3389/fphar.2021.681424

FIGURE 3.

FIGURE 3

The DN prevention in STZ-induced rats by VHH-0031. Rats were administrated with saline, benazepril (10 mg kg−1), VHH-0031 (0.1 or 0.5 mg kg−1) for 6 weeks, and then killed for study (A) Blood glucose level (B) Body weight change (C) The ratio of kidney weight to body weight (D) The level of blood urea nitrogenand serum creatinine in the serum by experimental kit (E) The level of IL-6 in the serum by ELISA (F) Evaluation of mesangial expansion, mesangial metrix caused by glycogen stimulation and glomerulosclerosis caused by collagen deposition in the kidney by H&E, PAS, Masson staining, Bar = 100 μm.The black arrow points to glomerular mesangial hyperplasia, the green arrow points to renal tubule congestion and edema. Quantification analysis of mesangial matrix index by PAS staining (G) and glomerulosclerosis by Masson’s trichrome staining (H) in kidneys Bar = 100 μm. Data represents the mean ± SD for six rats per group. Control: SD rats without STZ treatment, Model: SD rats with STZ treatment, Benazepril 10 mg kg−1: SD rats with STZ treatment in presence of benazepril (10 mg kg−1), VHH-0031 0.1 and 0.5 mg kg−1: SD rats with STZ treatment in presence of the recombinant anti-IL-6R fusion proteins (0.1 and 0.5 mg kg−1). **p < 0.01, ***p < 0.001 vs control group, # p < 0.05, ## p < 0.01, ### p < 0.001 vs model group.